Similarly, an ongoing stage 2 clinical trial (NCT03473925) on advanced microsatellite-stable CRC, castration-resistant prostate cancer, and NSCLC is investigating NET formation during combination therapy with a CXCR1/2 antagonist (navarixin) and PD1 inhibitor (pembrolizumab). Here, CXCR1 is linked to prostate cancer.